Cargando…

Enhanced 3T3-L1 Differentiation into Adipocytes by Pioglitazone Pharmacological Activation of Peroxisome Proliferator Activated Receptor-Gamma (PPAR-γ)

SIMPLE SUMMARY: Pioglitazone is a potent activator of PPAR-γ, a transcriptional factor that is involved in insulin sensibilization and adipocyte differentiation. Here, we propose an optimized methodology for adipocyte differentiation that is critical for secretome release. To achieve this goal, diff...

Descripción completa

Detalles Bibliográficos
Autores principales: Teixeira, Catarina, Sousa, André P., Santos, Inês, Rocha, Ana Catarina, Alencastre, Inês, Pereira, Ana Cláudia, Martins-Mendes, Daniela, Barata, Pedro, Baylina, Pilar, Fernandes, Rúben
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9219682/
https://www.ncbi.nlm.nih.gov/pubmed/35741327
http://dx.doi.org/10.3390/biology11060806
_version_ 1784732173846183936
author Teixeira, Catarina
Sousa, André P.
Santos, Inês
Rocha, Ana Catarina
Alencastre, Inês
Pereira, Ana Cláudia
Martins-Mendes, Daniela
Barata, Pedro
Baylina, Pilar
Fernandes, Rúben
author_facet Teixeira, Catarina
Sousa, André P.
Santos, Inês
Rocha, Ana Catarina
Alencastre, Inês
Pereira, Ana Cláudia
Martins-Mendes, Daniela
Barata, Pedro
Baylina, Pilar
Fernandes, Rúben
author_sort Teixeira, Catarina
collection PubMed
description SIMPLE SUMMARY: Pioglitazone is a potent activator of PPAR-γ, a transcriptional factor that is involved in insulin sensibilization and adipocyte differentiation. Here, we propose an optimized methodology for adipocyte differentiation that is critical for secretome release. To achieve this goal, different concentrations of pioglitazone (0–10 µM) were tested and the adipocyte lipidic accumulation was studied. The secretome was then incubated with prostatic cells and macrophages, and the aggressiveness and expression of the inflammatory cytokines were evaluated. We concluded that pioglitazone enhanced adipocyte differentiation and secretome production, making this secretome an excellent adiposity study model. ABSTRACT: Despite the primary function of pioglitazone in antidiabetic treatment, this drug is a potent inducer of PPAR-γ, a crucial receptor that is involved in adipocyte differentiation. In this work, we propose an optimized methodology to enhance the differentiation of 3T3-L1 fibroblasts into adipocytes. This process is crucial for adipocyte secretome release, which is fundamental for understanding the molecular mechanisms that are involved in obesity for in vitro studies. To achieve this, a pioglitazone dose-response assay was determined over a range varying from 0 to 10 µM. Lipid accumulation was evaluated using Oil-Red-O. The results showed that 10 µM pioglitazone enhanced differentiation and increased secretome production. This secretome was then added into two cell lines: PC3 and RAW264.7. In the PC3 cells, an increase of aggressiveness was observed in terms of viability and proliferation, with the increase of anti-inflammatory cytokines. Conversely, in RAW264.7 cells, a reduction of viability and proliferation was observed, with a decrease in the overexpression of pro-inflammatory cytokines. Overall, the present work constitutes an improved method for adipocyte secretome production that is suitable for experimental biology studies and that could help with our understanding of the molecular mechanisms underlying adiposity influence in other cells.
format Online
Article
Text
id pubmed-9219682
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-92196822022-06-24 Enhanced 3T3-L1 Differentiation into Adipocytes by Pioglitazone Pharmacological Activation of Peroxisome Proliferator Activated Receptor-Gamma (PPAR-γ) Teixeira, Catarina Sousa, André P. Santos, Inês Rocha, Ana Catarina Alencastre, Inês Pereira, Ana Cláudia Martins-Mendes, Daniela Barata, Pedro Baylina, Pilar Fernandes, Rúben Biology (Basel) Article SIMPLE SUMMARY: Pioglitazone is a potent activator of PPAR-γ, a transcriptional factor that is involved in insulin sensibilization and adipocyte differentiation. Here, we propose an optimized methodology for adipocyte differentiation that is critical for secretome release. To achieve this goal, different concentrations of pioglitazone (0–10 µM) were tested and the adipocyte lipidic accumulation was studied. The secretome was then incubated with prostatic cells and macrophages, and the aggressiveness and expression of the inflammatory cytokines were evaluated. We concluded that pioglitazone enhanced adipocyte differentiation and secretome production, making this secretome an excellent adiposity study model. ABSTRACT: Despite the primary function of pioglitazone in antidiabetic treatment, this drug is a potent inducer of PPAR-γ, a crucial receptor that is involved in adipocyte differentiation. In this work, we propose an optimized methodology to enhance the differentiation of 3T3-L1 fibroblasts into adipocytes. This process is crucial for adipocyte secretome release, which is fundamental for understanding the molecular mechanisms that are involved in obesity for in vitro studies. To achieve this, a pioglitazone dose-response assay was determined over a range varying from 0 to 10 µM. Lipid accumulation was evaluated using Oil-Red-O. The results showed that 10 µM pioglitazone enhanced differentiation and increased secretome production. This secretome was then added into two cell lines: PC3 and RAW264.7. In the PC3 cells, an increase of aggressiveness was observed in terms of viability and proliferation, with the increase of anti-inflammatory cytokines. Conversely, in RAW264.7 cells, a reduction of viability and proliferation was observed, with a decrease in the overexpression of pro-inflammatory cytokines. Overall, the present work constitutes an improved method for adipocyte secretome production that is suitable for experimental biology studies and that could help with our understanding of the molecular mechanisms underlying adiposity influence in other cells. MDPI 2022-05-24 /pmc/articles/PMC9219682/ /pubmed/35741327 http://dx.doi.org/10.3390/biology11060806 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Teixeira, Catarina
Sousa, André P.
Santos, Inês
Rocha, Ana Catarina
Alencastre, Inês
Pereira, Ana Cláudia
Martins-Mendes, Daniela
Barata, Pedro
Baylina, Pilar
Fernandes, Rúben
Enhanced 3T3-L1 Differentiation into Adipocytes by Pioglitazone Pharmacological Activation of Peroxisome Proliferator Activated Receptor-Gamma (PPAR-γ)
title Enhanced 3T3-L1 Differentiation into Adipocytes by Pioglitazone Pharmacological Activation of Peroxisome Proliferator Activated Receptor-Gamma (PPAR-γ)
title_full Enhanced 3T3-L1 Differentiation into Adipocytes by Pioglitazone Pharmacological Activation of Peroxisome Proliferator Activated Receptor-Gamma (PPAR-γ)
title_fullStr Enhanced 3T3-L1 Differentiation into Adipocytes by Pioglitazone Pharmacological Activation of Peroxisome Proliferator Activated Receptor-Gamma (PPAR-γ)
title_full_unstemmed Enhanced 3T3-L1 Differentiation into Adipocytes by Pioglitazone Pharmacological Activation of Peroxisome Proliferator Activated Receptor-Gamma (PPAR-γ)
title_short Enhanced 3T3-L1 Differentiation into Adipocytes by Pioglitazone Pharmacological Activation of Peroxisome Proliferator Activated Receptor-Gamma (PPAR-γ)
title_sort enhanced 3t3-l1 differentiation into adipocytes by pioglitazone pharmacological activation of peroxisome proliferator activated receptor-gamma (ppar-γ)
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9219682/
https://www.ncbi.nlm.nih.gov/pubmed/35741327
http://dx.doi.org/10.3390/biology11060806
work_keys_str_mv AT teixeiracatarina enhanced3t3l1differentiationintoadipocytesbypioglitazonepharmacologicalactivationofperoxisomeproliferatoractivatedreceptorgammapparg
AT sousaandrep enhanced3t3l1differentiationintoadipocytesbypioglitazonepharmacologicalactivationofperoxisomeproliferatoractivatedreceptorgammapparg
AT santosines enhanced3t3l1differentiationintoadipocytesbypioglitazonepharmacologicalactivationofperoxisomeproliferatoractivatedreceptorgammapparg
AT rochaanacatarina enhanced3t3l1differentiationintoadipocytesbypioglitazonepharmacologicalactivationofperoxisomeproliferatoractivatedreceptorgammapparg
AT alencastreines enhanced3t3l1differentiationintoadipocytesbypioglitazonepharmacologicalactivationofperoxisomeproliferatoractivatedreceptorgammapparg
AT pereiraanaclaudia enhanced3t3l1differentiationintoadipocytesbypioglitazonepharmacologicalactivationofperoxisomeproliferatoractivatedreceptorgammapparg
AT martinsmendesdaniela enhanced3t3l1differentiationintoadipocytesbypioglitazonepharmacologicalactivationofperoxisomeproliferatoractivatedreceptorgammapparg
AT baratapedro enhanced3t3l1differentiationintoadipocytesbypioglitazonepharmacologicalactivationofperoxisomeproliferatoractivatedreceptorgammapparg
AT baylinapilar enhanced3t3l1differentiationintoadipocytesbypioglitazonepharmacologicalactivationofperoxisomeproliferatoractivatedreceptorgammapparg
AT fernandesruben enhanced3t3l1differentiationintoadipocytesbypioglitazonepharmacologicalactivationofperoxisomeproliferatoractivatedreceptorgammapparg